Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Number of NRF-rated researchers increases in 2012
2012-10-29

29 October 2012

Three researchers at the University of the Free State received B-ratings for 2013 from the National Research Foundation (NRF). Prof. Johan Henning, Dean of Law, obtained the highest rating in his field of mercantile law in South Africa, a B1.

Prof. Jackie Naudé from Classical and Near Eastern Studies and Prof. Dingie Janse van Rensburg, Professor Extraordinary at the Centre for Health Systems Research and Development, also obtained B3-ratings. Prof. Naudé is the first B-rated researcher in the Faculty of Humanities.
Prof. Helene Strauss obtained the highest rating (Y1) for a UFS young scholar in the Humanities.
In total, the NRF rated researchers at the UFS grew from 95 in 2011 to 109 in 2012, a growth of almost 15 percent.
The NRF ratings committee consist of three reviewers from South Africa and three from abroad. A rating is valid for six years and researchers must reapply for rating before the end of that period.
For a B1-rating all reviewers must be firmly convinced that the applicant enjoys considerable international recognition for the high quality of the researcher’s recent output, with some indicating that the researcher is a leading international scholar in a field. For a B3-rating most of the reviewers must be convinced that the researcher enjoys international recognition for the high quality and impact of the research.
Prof. Jonathan Jansen, Vice-Chancellor and Rector, said in the UFS Research Report “The UFS now has among the highest number of NRF-rated scientists per size of the academic faculty and we have seen the productivity graph bear witness to a record growth in our funded research outputs; we have won our first-ever NRF/DST Research Chairs. In each of these achievements, the excellence we seek comes with and through the diversity we celebrate.”
More ratings and renewals were expected by the time of Bult went to print.. More than 35 researchers applied for ratings or renewal of ratings.
  • Colleagues who were admitted to the prestigious Academy of Science of South Africa (ASSAf) are Profs. Pumla Gobodo-Madikizela, Driekie Hay, Heidi Hudson, Lodewyk Kock, Odireleng Ntwaeaborwa, Hugh Patterton, Ian Phimister and Melanie Walker. ASSAf was established in 1996 with the mission of using science for the benefit of society. New members are elected after nomination by four existing members (at least two of whom do so from personal knowledge of the candidate). ASSAf has some 350 members and represents South Africa in the international community of science academies.
  • Dr Marieka Gryzenhout of Plant Sciences became a member of South African Young Academy of Science (SAYAS). SAYAS celebrated its first year in 2012. It was launched as a means to enable South Africa’s young scientists to fully participate in locally and internationally relevant research and development agendas. Prof. Aldo Stroebel, Director: Internationalisation, is also a member of SAYAS.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept